What's Happening?
LSL Pharma Group Inc., a Canadian pharmaceutical company, has signed a binding term sheet with Instapill Private Limited to supply private label Loratadine 10 mg rapid dissolve tablets (RDT) to Canadian retailers. This product is bioequivalent to Claritin
RDT and targets the growing over-the-counter (OTC) allergy market in Canada, which is valued at $60 million and expanding at 8% annually. The agreement follows Juno OTC's successful collaboration with Instapill for Loperamide 2 mg RDT, which has seen widespread distribution under private labels across major Canadian retailers. The partnership aims to leverage Instapill's rapid dissolve technology to enhance patient compliance and convenience, with plans to expand into additional OTC RDT products.
Why It's Important?
The agreement between LSL Pharma and Instapill is significant as it positions LSL Pharma to capitalize on the growing demand for OTC allergy medications in Canada. By expanding its product offerings with innovative dosage formats, LSL Pharma aims to strengthen its presence in the consumer health space and drive sustainable revenue growth. The collaboration with Instapill, a leader in rapid dissolve technology, provides LSL Pharma with access to a pipeline of products that can enhance patient compliance and convenience. This strategic move is expected to boost LSL Pharma's market share and establish Juno OTC as a leading supplier of high-quality private label RDT products in Canada.
What's Next?
The commercial launch of Loratadine 10 mg RDT is planned for June 2027, subject to Health Canada approval. LSL Pharma is actively advancing additional OTC RDT products to build a broad portfolio across multiple therapeutic categories. With more than 40 products currently on the market and 10 new products expected to launch over the next 12 months, Juno OTC is rapidly increasing its presence in the Canadian pharmaceutical OTC market. The company aims to continue leveraging its partnership with Instapill to expand its product offerings and drive long-term shareholder value.
